Compositions for treating KCA3.1 channel-mediated diseases comprising phenylalkylcarbamate compounds
Phenylalkyl carbamate compounds, like solriamfetol, inhibit KCa3.1 channels to address the progression of fibrotic, autoimmune, and cancer diseases by reducing inflammation and fibrosis.
Patent Information
- Application Number
- JP2023507695
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-08-03
- Filing Date
- 2021-07-29
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-07-29
AI Technical Summary
Current treatments for channel-mediated diseases, such as fibrotic, autoimmune, and cancer diseases, do not effectively target the KCa3.1 channels, which play a crucial role in disease progression.
A composition containing phenylalkyl carbamate compounds, including solriamfetol, is developed to suppress the expression of KCa3.1 channels, thereby inhibiting inflammation and fibrosis.
The phenylalkyl carbamate compounds effectively suppress KCa3.1 channel expression, reducing inflammation and fibrosis in both in vitro and in vivo models, offering potential therapeutic benefits for fibrotic, autoimmune, and cancer diseases.
Smart Images

Figure 0007577191000013 
Figure 0007577191000014 
Figure 0007577191000015
Abstract
Description
[Technical field]
[0001] The present invention relates to a K-containing phenyl alkyl carbamate compound. Ca 3.1 Regarding the composition for treating channel-mediated diseases, the composition contains solriamfetol, which has been used in the past as a treatment for sleepiness, i.e., a phenylalkylcarbamate compound represented by 2-amino-3-phenylpropylcarbamate, as an active ingredient, and acts to inhibit the K channel in the cell membrane. Ca 3.1 By suppressing the expression of K Ca 3.1 Pharmaceutical compositions that can be used to treat channel-mediated diseases, such as fibrotic diseases, autoimmune diseases and cancer diseases. [Background technology]
[0002] In the human body, K Ca 3.1 channels are distributed in non-excitable cells such as fibroblasts, hepatic stellate cells, vascular endothelial cells, nerve cells, cancer cells, and immune cells (T cells, B cells). + The channel is a Ca channel that is activated by hyperpolarization of the membrane voltage. 2+ It plays a role in activating cells by increasing the influx of Ca into cells. 2+ K acts as a second messenger or a co-factor for various enzymes in cells and plays a very important role in intracellular signal transduction processes. Ca 3.1 Channel activation causes intracellular Ca 2+ Increased levels of NF-κB promote cell proliferation, epithelial-mesenchymal transition, cell migration, the formation of the extracellular matrix, and the production and secretion of substances such as nitric oxide.
[0003] The formation of myofibroblasts (or activated hepatic stellate cells) is the most important step in the fibrosis process, and occurs through epithelial-mesenchymal transition. When myofibroblasts are formed and hepatic stellate cells are activated, these cells actively proliferate, and these cells actively form extracellular matrix, which actively promotes fibrosis. The epithelial-mesenchymal transition in which myofibroblasts are formed from vascular endothelial cells or epithelial cells is initiated by Ca 2+ It is known that this process is dependent on the fibrosis-inducing factor TGF β The epithelial-mesenchymal transition induced by Ca 2+ It is known that it is sensitive to Ca 3.1 Channels are involved in the intracellular Ca2+ transport in myofibroblasts and hepatic stellate cells. 2+ by regulating epithelial-mesenchymal transition.
[0004] K Ca 3.1 When the channel is activated, such K + Different reactions occur depending on the cells in which the channel is expressed. It increases inflammation and immune responses through immune cell proliferation and cytokine secretion through immune cells. It promotes angiogenesis through vascular endothelial cells and induces vascular relaxation through the secretion of nitric oxide. It also induces fibrotic diseases through fibroblasts and hepatic stellate cells. That is, it generates myofibroblasts and activates hepatic stellate cells, inducing the production of extracellular matrix such as collagen, contributing to the formation of connective tissue. It also plays an important role in the proliferation and metastasis of some cancer cells. Therefore, K Ca It can be speculated that the 3.1 channel plays a crucial role in the progression of inflammatory and autoimmune, fibrotic and cancer diseases.
[0005] Pro-inflammatory agents such as cytokines and H2O2 amplify immune and inflammatory responses, including proliferation of immune cells, and TGF β Pro-fibrotic agents, including growth factors such as PDGF and inflammatory factors, amplify the fibrotic response.Ca 3.1 channel expression, which amplifies the inflammatory and immune responses caused by proinflammatory and profibrotic factors, as well as the fibrotic response. Ca 3.1 Increased expression of the channel plays an important role
[0006] In this way, K Ca 3.1 Increased expression of the channel promotes the progression of proliferative diseases such as fibrosis and cancer, and inflammatory diseases such as autoimmune diseases. Ca 3.1 Channel-mediated diseases. Ca Efforts are ongoing to develop therapeutic agents for inflammatory and autoimmune diseases, fibrotic diseases, and cancer diseases using 3.1 channel inhibitors. Ca The 3.1 inhibitor senicapoc is being developed for the treatment of various inflammatory and autoimmune diseases, including sickle cell anemia, and fibrotic diseases.
[0007] The present inventors have reported on the development of a K-type steroid containing modafinil and its derivatives as active ingredients, which have been used in narcolepsy treatments, in U.S. Patent US9,259,412B2 (Patent Document 1) and its family patent, Korean Patent No. 10-1414831, both of which are owned by the Ewha Women's University Industry-Academic Cooperation Group. Ca 3.1 A composition for treating or preventing a channel-mediated disease is provided, wherein Ca Examples of 3.1 channel-mediated diseases include sickle cell anemia, immune diseases including acute immune responses or autoimmune diseases, cancer diseases including prostate or pancreatic cancer, traumatic brain injury, degenerative neurological diseases and secretory diarrhea.
[0008] Solriamfetol, i.e., 2-amino-3-phenylpropyl carbamate, is a drug for treating drowsiness, and has been developed and sold by SK Corporation of Korea under the product name "Sunosi". In relation to this, SK Corporation's U.S. Patents US5,955,499B2 (Patent Document 2) and US6,140,532B2 (Patent Document 3) and their family patents, Korean Registered Patents Nos. 10-197892 and 10-173863, report that solriamfetol and its derivatives are useful as central nervous system therapeutics, particularly antidepressants and antianxiety agents.
[0009] In addition, U.S. Patent US9,464,041B2 (Patent Document 4) and its family patent, Korean Patent Publication No. 10-2019-105675, disclose a method for treating or preventing fatigue caused by diseases such as depression, cancer, multiple sclerosis, Parkinson's disease, Alzheimer's disease, chronic fatigue, fibromyalgia, chronic pain, traumatic brain injury, AIDS, and osteoarthritis using solriamfetol and its derivatives, and U.S. Patent US10,351,517B2 (Patent Document 5) and its family patent, Korean Patent Registration No. 10-1335941, disclose a method for treating sleep-wake disorders including excessive daytime sleepiness and pathological somnolence. [Prior art documents] [Patent documents]
[0010] [Patent Document 1] U.S. Patent No. 9,259,412 (Korean Patent No. 10-1414831) [Patent Document 2] U.S. Patent No. 5,955,499 (Korean Patent No. 10-197892) [Patent Document 3] U.S. Patent No. 6,140,532 (Korean Patent No. 10-173863) [Patent Document 4] U.S. Patent No. 9,464,041 (Korean Patent Publication No. 10-2019-105675) [Patent Document 5] U.S. Patent No. 10,351,517 (Korean Patent No. 10-1335941) Summary of the Invention [Problem to be solved by the invention]
[0011] The present inventors have + Using a substance that inhibits the K channel Ca 3.1 While researching methods for treating channel-mediated diseases, we were surprised to find that phenylalkylcarbamate compounds, including solriamfetol, which has been used as a treatment for sleepiness, have the potential to inhibit K Ca The present invention was completed by grasping the possibility that the expression of the 3.1 channel can be inhibited and proving this possibility through various experiments.
[0012] Therefore, the object of the present invention is to provide a new K-compound containing the above-mentioned phenyl alkyl carbamate compound as an active ingredient. Ca 3.1 To provide a composition for treating channel-mediated diseases. [Means for solving the problem]
[0013] K according to the present invention Ca 3.1 The composition for treating a channel-mediated disease is characterized by comprising a phenylalkylcarbamate compound represented by the following [Structural Formula 1] or a pharma- ceutically acceptable salt thereof as an active ingredient.
[0014] [ka] In the above [Structural Formula 1], R1 is one or two functional groups selected from hydrogen, halogen, hydroxy, amine, nitro, hydrogen sulfide, methyl, methyl halogen, ethyl, propyl, methoxy, ethoxy, vinyl, and aryl, R2 and R3 are each one functional group selected from hydrogen, methyl, ethyl, propyl, and amide, and the * symbol denotes a chiral center.
[0015] In addition, the present invention Ca 3.1 The composition for treating a channel-mediated disease is characterized by comprising a compound in which R2 and R3 in the above [Structural Formula 1] are hydrogen.
[0016] In addition, the present invention Ca 3.1 The composition for treating a channel-mediated disease is characterized by comprising a compound in which, in the above [Structural Formula 1], R1 is one or two functional groups selected from hydrogen, F, Cl, Br, and I.
[0017] In addition, the present invention Ca 3.1 The composition for treating channel-mediated diseases is characterized by comprising a compound in which, in the above [Structural Formula 1], R1 is one or two F, and R2 and R3 are each a functional group selected from hydrogen, methyl, and amide.
[0018] The compound represented by the above formula (1) is characterized in that it is a chiral compound having an R-isomer or S-isomer content of 90% or more.
[0019] In addition, the compound represented by the above [Structural Formula 1] is 2-Amino-3-phenylpropylcarbamate; 2-Amino-3-(3-fluorophenyl)propyl carbamate; 2-Amino-3-(3,4-dichlorophenyl)propylcarbamate; 2-Amino-3-phenylpropyl methylcarbamate; 2-Amino-3-phenylpropyl(aminocarbonyl)carbamate; 2-Amino-3-(4-hydroxyphenyl)propylcarbamate; 2-amino-3-[3-(trifluoromethyl)phenyl]propyl carbamate.
[0020] In addition, the K Ca 3.1 Channel-mediated diseases are characterized by fibrotic diseases, including liver and lung fibrosis, autoimmune diseases, and cancer diseases. Effect of the Invention
[0021] The compound of formula 1 according to the present invention exhibits K Ca In addition to suppressing the expression of the 3.1 channel, it also has the effect of suppressing inflammation and fibrosis. Furthermore, in vivo experiments on a mouse model with induced liver disease confirmed that it also has the effect of suppressing inflammation and fibrosis.
[0022] Therefore, the compound of formula 1 is a K Ca It is expected that the present invention can be usefully used in new pharmaceutical compositions for treating 3.1 channel-mediated diseases such as various inflammatory and autoimmune diseases, fibrotic diseases, and cancer diseases, and can also be developed into veterinary drugs, if necessary. [Brief description of the drawings]
[0023] [Figure 1] FIG. 2 shows the effect of the compound of formula 2 of the present invention on KCa3.1 current in fibroblasts. [Diagram 2] FIG. 2 shows the effect of the compounds of structural formulas 3 to 8 of the present invention on KCa3.1 current in fibroblasts. [Diagram 3] FIG. 1 shows the effect of the compounds of structural formulas 2 to 8 of the present invention on the expression of inflammatory markers in fibroblasts exposed to inflammation-inducing lipopolysaccharides (LPS) for 24 hours. [Figure 4]FIG. 1 shows the effect of the compounds of structural formulas 2 to 8 of the present invention on the expression of fibrosis markers in fibroblasts exposed to fibrosis-inducing TGFβ for 24 hours. [Diagram 5] FIG. 2 is a diagram showing the fibrosis-inhibiting effect of the compound of structural formula 2 according to the present invention in a mouse model in which pulmonary fibrosis was induced by bleomycin, as confirmed by Masson's trichrome staining of collagen. [Figure 6] FIG. 2 is a graph showing the effect of the compound of structural formula 2 according to the present invention on the expression of mRNA, a fibrosis marker, in a mouse model in which pulmonary fibrosis was induced by bleomycin. [Figure 7] FIG. 1 shows the results of confirming the fibrosis-inhibitory effect of the compound of structural formula 2 according to the present invention by Masson's trichrome staining for collagen in a mouse model in which liver fibrosis was induced by feeding a CDAHFD. [Figure 8] FIG. 2 shows the effect of the compound of structural formula 2 according to the present invention on the expression of mRNA, a fibrosis marker, in a mouse model in which liver fibrosis was induced by feeding a CDAHFD. BEST MODE FOR CARRYING OUT THEINVENTION
[0024] The phenyl alkyl carbamate compound of the above structural formula 1 according to the present invention specifically includes compounds of the following structural formulas 2 to 8.
[0025] [ka]
[0026] [ka]
[0027] [ka]
[0028] [ka]
[0029] [ka]
[0030] [ka]
[0031] [ka]
[0032] The chemical names of the compounds of the above structural formulas 2 to 8 and the code names given by the present inventors are as follows.
[0033] [Table 1]
[0034] The compound of formula 2 is known by the common name solriamfetol and is currently used as a drug for treating drowsiness. The method for preparing the compound of formula 3 is disclosed in US Patent US6,140,532B2 and Korean Patent No. 10-173863, which is a Family Patent, and the compound of formula 4 can be prepared by the method disclosed in US Patent Publication US2005 / 0080268A1.
[0035] The method for producing the compound of formula 5 is disclosed in US Patent US5,705,640B2, the method for producing the compound of formula 6 is disclosed in US Patent US9,403,761B2 or its family patent, Korean Patent Publication No. 10-2016-0126988, and the compound of formula 7 can be produced by the method described in [Example 9] of US Patent US6,140,532B2 and [Example 9] of International Patent Publication WO98 / 15526.
[0036] The compound of formula 8 can be prepared by the method described in [Example 48A] of US Patent US9,180,120B2 or its family patent, Korean Patent Publication No. 10-2013-0138216, filed by Bayer.
[0037] For reference, the Bayer patent states that the compound of structural formula 8 can be used for liver cirrhosis, etc. However, the Bayer patent aims to treat liver cirrhosis, including cardiovascular disorders, by suppressing the action of vasopressin, an antidiuretic hormone, as a V1a and V2 receptor antagonist, and by treating heart failure and renal and hemodynamic effects.
[0038] On the other hand, in the present invention, the compound of the above structural formula 8 is K Ca Since the present invention aims to solve the direct cause of fibrosis by suppressing the expression of the 3.1 channel, it can be said that the present invention is clearly different from the cirrhosis treatment concomitantly obtained by the Bayer patent.
[0039] The pharmaceutical composition according to the present invention includes a pharma- ceutically acceptable salt of the compound of the above formula 1. Here, the term "pharma-ceutically acceptable salt" generally includes metal salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like.
[0040] The pharmaceutical compositions according to the present invention also include all solvates and hydrates of the compounds of formula 1, including racemates and all possible stereoisomers, and may also include crystalline or non-crystalline forms of each compound.
[0041] The pharmaceutical composition according to the present invention can be formulated by a conventional method into the form of tablets, pills, powders, granules, capsules, suspensions, oral liquids, emulsions, syrups, aerosols, sterile injection solutions, etc. Also, it can be administered orally or parenterally depending on the purpose of use, and in parenteral administration, the injection method can be selected from topical application on the skin, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and intrathoracic injection.
[0042] The dosage of the pharmaceutical composition according to the present invention may vary depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease. The preferred daily dosage is 0.2-20 mg / kg, more preferably 0.5-10 mg / kg, based on the active ingredient, and may be administered once or twice a day, but is not limited thereto. EXAMPLES
[0043] The pharmacological effects of the phenyl alkyl carbamate compounds according to the present invention will now be described.
[0044] 1) Experimental Method 1-1) Fibroblast cell culture Fibroblast cells (CRL-2795; American Type Culture Collection, VA) were cultured in Dulbecco's Modified Eagle Medium (Hyclone, Logan, UT). All cells were maintained at 37°C under 5% carbon dioxide humidified conditions. Fibroblast cells cultured in this manner were able to secrete lipopolysaccharides (LPS), an inflammatory agent, and transforming growth factor (TGF), a fibrosis-inducing factor. βand the compounds of structural formulas 2 to 8 of the present invention (hereinafter referred to as SF-2 to SF-8 compounds) for 24 hours, and then the anti-inflammatory and anti-fibrotic effects were tested.
[0045] 1-2) Establishment of a mouse model of pulmonary fibrosis In order to confirm the fibrosis-inhibiting effect of the SF-2 compound according to the present invention, the following experiment was carried out. First, C57BL / 6 wild-type mice (purchased from Oriental Bio Co., Ltd.) were divided into three groups of 6-8 mice each, which were used as a disease-induced group, a drug-administered group, and a normal control group. The test mice in each group were treated as follows.
[0046] (1) Disease-induced group: 1.5 units of bleomycin were injected into the airways of the test mice to induce pulmonary fibrosis. Next, the mice were intraperitoneally injected with distilled water (100 mg / kg) five times a week in the same amount as that of the SF-2 compound administered to the drug administration groups below. In the attached figures, BLM (bleomycin) refers to this disease-induced group.
[0047] (2) Drug administration group: 1.5 units of bleomycin was injected into the airway of the test mice, and then the SF-2 compound of the present invention was intraperitoneally injected (100 mg / kg) 5 times a week. In the attached drawings, BLM+SF-2 refers to this drug administration group.
[0048] (3) Normal control group: The same amount of distilled water as that of bleomycin injected into the disease-induced group was injected into the airway. Then, the same amount of distilled water as that of SF-2 compound administered to the drug-administered group was intraperitoneally injected five times a week. In the attached figures, C or Control refers to this normal control group.
[0049] After drug treatment for 4 weeks in the above manner, each mouse model group was killed instantly by administering an overdose of anesthetic, and the lungs were excised and used for the next test.
[0050] 1-3) Construction of a mouse model of fatty liver disease In order to confirm the therapeutic effect of the SF-2 compound of the present invention on liver inflammation and fibrosis, the following experiment was carried out. First, C57BL / 6 wild-type mice (purchased from Oriental Bio Co., Ltd.) were divided into three groups of 6 to 8 mice each, which were used as a disease-induced group, a drug-administered group, and a normal control group. The test mice in each group were treated as follows.
[0051] (1) Disease-induced group: Test mice were fed a CDAHFD (choline deficient, L-amino acid-defined, high-fat diet with 0.1% methionine. A06071302, Research Diets, New Brunswick, NJ) to induce fatty liver disease and fibrosis. Next, distilled water was administered five times a week using a sonde (oral tube) in the same amount as that of the SF-2 compound administered to the drug administration group described below. In the attached figures, CDAHFD refers to such a disease-induced group.
[0052] (2) Drug-administered group: the test mice were fed the CDAHFD and administered the SF-2 compound of the present invention (100 mg / kg / day) five times a week. In the attached drawings, CDAHFD+SF-2 refers to this drug-administered group.
[0053] (3) Normal control group: Test mice were fed normal food. Then, distilled water was administered five times a week using a sonde (oral tube) in the same amount as that of the SF-2 compound administered to the drug administration group. In the attached figures, C or Control refers to this normal control group.
[0054] After the mouse models in each group were treated with drugs for 16 weeks as described above, they were instantly killed by administering an overdose of anesthetic, and the livers were excised and used for the next test.
[0055] 1-4) Preparation of paraffin tissue specimens of lung and liver tissues and observation of morphological changes The lung and liver tissues extracted from the mouse model were fixed in a paraformaldehyde solution and cut into pieces of 1-2 mm thickness. The cut tissues were embedded in paraffin, cut into pieces of 4 μm thickness, and the paraffin was removed with xylene, and then the xylene was removed with ethanol and washed with tap water to prepare paraffin tissue specimens.
[0056] Immunohistochemistry of the lung and liver tissues for collagen, a fibrosis marker, was performed using Masson's trichrome staining method.
[0057] 1-5) Real-time PCR analysis The expression levels of mRNA of inflammation or fibrosis factors in lung and liver tissues excised from the mouse model were measured by real-time polymerase chain reaction. RNA from the tissues was isolated using TRIzol reagent (Molecular Research Center, Cincinnati, OH), and single-stranded cDNA was synthesized using BcaBEST polymerase (Takara Shuzo), followed by polymerase chain reaction.
[0058] The primer sequences (SEQ ID NOs: 1 to 30) used for the proinflammatory cytokines and fibrosis markers are shown in Tables 2 and 3 below.
[0059] [Table 2]
[0060] [Table 3]
[0061] 1-6) Electrophysiological analysis The whole cell current was measured in single cultured fibroblasts by the patch-clamp technique. A voltage ramp from -100mV to +100mV was applied to whole-cell voltage clamp cells through a fine glass electrode, and the resulting current was amplified by an amplifier (EPC-10, HEKA, Lambrecht, Germany) and recorded at a sampling rate of 1-4kHz.
[0062] The standard external solution contained 150 mM NaCl, 6 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM glucose, pH 7.4 (titrated with NaOH), and the fine glass electrode (pipette) solution contained 40 mM KCl, 100 mM K-aspartate, 2 mM MgCl2, 0.1 mM EGTA, 4 mM Na2ATP, 10 mM HEPES, pH 7.2 (titrated with KOH). 2+ The concentration was 5 mM EGTA with an appropriate amount of Ca 2+ was added and adjusted to 1 μM (calculated with CaBuf; G. Droogmans, Leuven, Belgium).
[0063] K Ca 3.1 Currents were isolated as follows: 1 μM Ca was injected into whole-cell voltage-clamped cells via a glass electrode. 2+ Inject K Ca 3.1 Current activation: K in the current recorded with 1-ethyl-2-benzimidazolinone (1-EBIO, 100 μM) Ca 3.1 Currents inhibited by the channel inhibitor TRAM-34 (10 μM) were Ca The recorded current was determined as 3.1 current and normalized by dividing by the cell capacitance.
[0064] 1-7) Statistical analysis The experimental results were expressed as the mean ± standard error (SEM). Statistical analysis was performed using Student's t-test, and a significance level of 0.05 or less was considered to be significant.
[0065] 2) Experimental results using cultured cells 2-1) K Ca 3.1 Effect of SF-2 compound on electric current
[0066] FIG. 1 shows the results of the K Ca 3.1 Effect of SF-2 compound on channel current. 2+ and K activated by 1-EBIO Ca The 3.1 current was inhibited by SF-2 in a concentration-dependent manner.
[0067] K Ca 3.1 The magnitude of the current was 37.49±1.51 pA / pF in cells not exposed to SF-2 compound, and 26.65±1.89 mV / pF, 11.69±1.66 mV / pF, 7.12±1.33 mV / pF, 1.87±0.24 mV / pF, and 1.95±0.44 mV / pF in cells exposed to 10, 30, 100, 300, and 1000 nM of SF-2 compound, respectively, and the K Ca 3.1 current was significantly decreased.
[0068] 2-2) K Ca 3.1 Effect of SF-3 to SF-8 compounds on electric current FIG. 2 of the accompanying drawings shows that K Ca 3.1 Effects of compounds SF-3 to SF-8 on channel current. 2+ and K activated by 1-EBIO Ca 3.1 Current was inhibited by the SF-3 to SF-8 compounds in a concentration-dependent manner.
[0069] 2-3) Inflammation suppression effect of SF-3 to SF-8 compounds The attached FIG. 3 shows the inhibitory effect of SF-2 to SF-8 compounds on inflammation induced by LPS in the fibroblasts. The inflammation-inducing effect of LPS was evaluated based on the level of mRNA expression of inflammatory markers. When the fibroblasts were exposed to LPS (10 ug / ml) for 24 hours, the amount of mRNA for inflammatory markers such as IL6 increased.
[0070] In addition, when fibroblasts were exposed to one of the compounds SF-2 to SF-8 together with LPS for 24 hours, the expression of mRNA for inflammatory markers was reduced. In the attached Figure 3, the test results are expressed as mean ± SE, n = 6 to 8, ## < 0.01 (normal control group vs. disease-induced group), ** < 0.01 (disease-induced group vs. drug-administered group).
[0071] 2-4) Fibrosis-inhibiting effect of SF-3 to SF-8 compounds Figure 4 of the accompanying drawings shows the effect of TGF- β FIG. 1 shows the fibrosis-inhibiting effect of compounds SF-2 to SF-8 on fibrosis induced by TGF- β The fibrosis-inducing effect of TGF-α was evaluated based on the level of mRNA expression of fibrosis markers. β Exposure to 10 ng / ml for 24 hours increased the levels of fibrosis markers α-smooth muscle actin (α-SMA), collagen 1α (Col1α), and collagen 3α (Col3α) mRNA.
[0072] In addition, fibroblasts were stimulated with TGF β When exposed to one of the compounds SF-2 to SF-8 for 24 hours, the expression of fibrosis markers decreased. In the attached Figure 4, the test results are expressed as mean ± SE, n = 6, ## < 0.01 (normal control group vs. disease-induced group), ** < 0.01 (disease-induced group vs. drug-administered group).
[0073] 3) Effect of SF-2 compound on mouse models of lung disease 3-1) Histological or immunohistochemical analysis results Paraffin tissue specimens were prepared from the lung tissues excised from the mouse model, and histoimmunological staining was performed for collagen, a fibrosis marker. Figure 5 attached herewith shows the results of Masson's trichrome staining of the lung tissues, confirming that the degree of fibrosis was increased in the disease-induced group (BLM) compared to the normal control group (sham control), and decreased in the drug-administered group (BLM+SF-2).
[0074] Therefore, it can be confirmed that the SF-2 compound of the present invention has an effect of suppressing pulmonary fibrosis. In the attached Figure 5, "BLM" means a disease-induced group treated with 1.5 units of bleomycin, and "BLM+SF-2" means a drug-administered group administered with 10 mg / kg / day or 100 mg / kg / day of the SF-2 compound together with 1.5 units of phleomycin.
[0075] 3-2) Analysis results for fibrosis marker mRNA expression To confirm the effect of the SF-2 compound on the expression of fibrosis marker mRNA in the mouse model, RT-PCR was performed for the fibrosis markers Col1α (collagen 1α), Col3α (collagen 3α), and α-SMA (α-smooth muscle actin).
[0076] As can be seen from FIG. 6, the mRNA expression levels of Col1α, Col3α, and α-SMA were significantly increased in the lung tissue of the disease-induced group (BLM) compared to the normal control group (C), indicating the progression of fibrosis. However, in the drug-administered group (BLM+SF-2), the mRNA expression levels of Col1α, Col3α, and α-SMA were significantly decreased, indicating the inhibition of fibrosis. These results suggest that the SF-2 compound of the present invention has an effect of inhibiting pulmonary fibrosis. In FIG. 6, the test results are expressed as mean ± SE, n=6, *<0.05, **<0.01.
[0077] 4) Experimental results on mouse models of liver disease 4-1) Histological or immunohistochemical analysis The attached Figure 7 shows the results of Masson's trichrome staining of collagen fibers in the liver tissue, and while the liver tissue of the normal control group (Sham control) is in a healthy state where fibrosis has not yet progressed, the liver tissue of the disease-induced group (CDAHFD) was stained blue, confirming that fibrosis has progressed. Meanwhile, in the liver tissue of the drug-administered group (CDAHFD+SF-2) in which the SF-2 compound was administered to the disease-induced group, the degree of blue staining was greatly reduced, and fibrosis was observed to be greatly suppressed.
[0078] 4-2) Analysis results for fibrosis marker mRNA expression To confirm the effect of the SF-2 compound on the expression of fibrotic marker mRNA in the mouse model, RT-PCR was performed for the fibrotic markers Col1α (collagen 1α), Col3α (collagen 3α), and α-SMA (α-smooth muscle actin).
[0079] As can be seen from Figure 8, the mRNA expression levels of Col1α, Col3α, and α-SMA were significantly increased in the lung tissue of the disease-induced group (CDAHFD) compared to the normal control group (C), indicating the progression of fibrosis. However, in the drug-administered group (CDAHFD+SF-2), the mRNA expression levels of Col1α, Col3α, and α-SMA were significantly decreased, confirming the inhibition of fibrosis.
[0080] These results suggest that the SF-2 compound of the present invention has an effect of suppressing liver fibrosis. In Figure 8, the test results are expressed as mean ± SE, n = 6, * < 0.05, ** < 0.01.
[0081] 5) Evaluation of experimental results From the above experimental results, it was confirmed that the compound of structural formula 2 of the present invention, i.e., solriamfetol, has fibrosis-inhibitory effect in a mouse model in which pulmonary fibrosis is induced by bleomycin and a mouse model in which liver fibrosis is induced by feeding CDAHFD.
[0082] In addition, the compounds of the structural formulas 2 to 8 of the present invention inhibit fibroblasts and TGF-α induced by LPS. β It was confirmed that the compounds of structural formulas 2 to 8 of the present invention have the effect of suppressing inflammation and fibrosis in fibroblasts in which fibrosis was induced by K. Ca This means that it has the effect of suppressing the expression of the 3.1 channel.
[0083] As mentioned above in the Background Art, K Ca The 3.1 channel plays a very important role in the progression of autoimmune and cancer diseases as well as inflammation and fibrosis. Therefore, various research groups and pharmaceutical companies around the world have developed K-channel inhibitors such as TRAM-34 and senicapoc. Ca 3.1 We are developing therapeutic agents for autoimmune diseases, inflammation, fibrosis, and cancer diseases using channel inhibitors.
[0084] In this way, K Ca When the 3.1 channel is inhibited, the progression of not only inflammatory and fibrotic diseases but also autoimmune diseases and cancer diseases can be inhibited, and therefore it is quite possible to conclude that the compounds of structural formulas 2 to 8 of the present invention are also effective in treating autoimmune diseases and cancer diseases.
[0085] In addition, in the present invention, due to practical limitations, the above-mentioned experiments were not performed on all compounds belonging to the above structural formula 1 compound. However, in consideration of chemical activity and metabolic mechanism in vivo, it is presumed that all of the above structural formula 1 compounds have similar pharmacological efficacy to the above structural formulas 2 to 8 compounds.
Claims
1. A composition for inhibiting fibrosis, comprising a phenylalkylcarbamate compound represented by the following structural formula 1 or a pharma- ceutical acceptable salt thereof. [Formula 1] In the above [Structural Formula 1], R1 is present 1 or 2 times and is selected from hydrogen, F, Cl, Br, and I; R2 and R3 are each present 1 time and are each selected from hydrogen, methyl, ethyl, propyl, and aminocarbonyl; and the * symbol denotes a chiral center.
2. The composition for inhibiting fibrosis according to claim 1, characterized in that, in the above [Structural Formula 1], R2 and R3 are hydrogen.
3. The composition for inhibiting fibrosis according to claim 1, characterized in that, in the above [Structural Formula 1], R1 is one or two F, and R2 and R3 each exist as one and are selected from hydrogen, methyl, and aminocarbonyl.
4. The composition for inhibiting fibrosis according to claim 1, characterized in that the compound represented by the structural formula 1 is a chiral compound having an R-isomer or S-isomer content of 90% or more.
5. 2-amino-3-phenylpropyl carbamate; 2-amino-3-(3-fluorophenyl)propyl carbamate; 2-amino-3-(3,4-dichlorophenyl)propyl carbamate; 2-amino-3-phenylpropyl methylcarbamate; 2-Amino-3-phenylpropyl(aminocarbonyl)carbamate; 2-amino-3-(4-hydroxyphenyl)propyl carbamate; A composition for inhibiting fibrosis, comprising any one selected from the group consisting of 2-amino-3-[3-(trifluoromethyl)phenyl]propyl carbamates.
6. The compound represented by the above [Structural Formula 1] is The composition for inhibiting fibrosis according to claim 1, characterized in that it is (R)-2-amino-3-phenylpropylcarbamate hydrochloride.
7. The composition for inhibiting fibrosis according to any one of claims 1 to 6, characterized in that the fibrosis is liver fibrosis or pulmonary fibrosis.
Citation Information
Patent Citations
Methods for treating or preventing fatigue
JP2012530779A
Treatment of cataplexy
JP2016512531A
KR10-173863
KR10-197892
Treatment of sleep-wake disorders
KR101335941B1
